Scientific Presentations
A Phase 1b/2 Study of the Polo-like Kinase 1 (PLK1) inhibitor, Onvansertib, in Combination with FOLFIRI and Bevacizumab for Second-Line Treatment of Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC)
D.H. Ahn, DO; A. Barzi, MD, PhD; M. Ridinger, PhD; E. Samuëlsz, M. Erlander, PhD; T.S. Bekaii-Saab, MD, FACP; H.J. Lenz, MD
A Phase 1b/2 Study of Onvansertib in Combination with FOLFIRI and Bevacizumab for Second-Line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS Mutation
A. Barzi, MD, H.J. Lenz, MD, E. Samuëlsz, M. Ridinger, PhD, M. Erlander, PhD, T. Bekaii-Saab, MD, D. Ahn, DO
A Phase 2 Study of PLK1 Inhibitor, Onvansertib, in Combination with Abiraterone and Prednisone in Patients with Abiraterone-Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC)
D.J. Einstein, MD; A. Choudhury, MD; P. Saylor; L. Werner, MD; M. Ridinger, PhD M. Erlander, PhD; G. Bubley, MD
A Phase 1b/2 Study of Onvansertib in Combination with FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS Mutation
A. Barzi, MD, H.J. Lenz, MD, E. Samuëlsz, M. Ridinger, PhD, M. Erlander, PhD, T. Bekaii-Saab, MD, D. Ahn, DO
Plasma-derived Circulating Tumor DNA (ctDNA) As a Surrogate Biomarker for Treatment Response with the Polo-like Kinase 1 (PLK1) Inhibitor, Onvansertib, in Combination with LDAC or Decitabine in Acute Myeloid Leukemia (AML)
Errin Samuëlsz, Latifa Hassaine, Marion Luebbermann, Brittany Ross, Peter Croucher, Mark Erlander, Maya Ridinger
Safety, Efficacy and Biomarker Analysis of a Phase 1 Study of Onvansertib, a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine or Decitabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Amer M. Zeidan, Gary Schiller, Tara Lin, Pamela S. Becker, Prapti Patel, Eunice Wang, Alexander Spira, Michaela Tsai, Maya Ridinger, Peter Croucher, Mark Erlander, Sandra Silberman
A Phase 2 Study of the Combination of PLK1 Inhibitor, Onvansertib, with Abiraterone and Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer
D.J. Einstein, A. Choudhury, P. Saylor, L. Werner, M. Ridinger, M. Erlander, G. Bubley
Polo-like Kinase 1 inhibitor Onvansertib Synergizes with Paclitaxel in Breast Cancer Carrying p53 Mutation
Antonio Giordano, Yueying Liu, Christiana Kappler, Yeonhee Park, Elizabeth Yeh, Mark Erlander, Stephen Ethier
A Phase 1b/2 Study of Onvansertib (PCM-075) in Combination with FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS Mutation
H.J. Lenz, D. Ahn, M. Ridinger, M. Erlander, A. Barzi
Polo-like Kinase 1 (PLK1) Inhibitor, Onvansertib, in Combination with Low-Dose Cytarabine or Decitabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Amer Zeidan, Alexander Spira, Pamela Becker, Prapti Patel, Gary Schiller, Michaela Tsai, Tara Lin, Eunice Wang, Maya Ridinger, Peter Croucher, Sandra Silberman, Mark Erlander
A Phase 2 Study of the Combination of PLK1 inhibitor, Onvansertib, with Abiraterone and Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
David J. Einstein, Atish Choudhury, Philip Saylor, Lillian Werner, Peter Croucher, Maya Ridinger, Mark Erlander, Glenn Bubley
A Phase 2 Study of Onvansertib (PCM-075) in Combination with Abiraterone and Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer
David J. Einstein, Atish Choudhury, Philip Saylor, Lillian Werner, Peter Croucher, Maya Ridinger, Mark Erlander, Glenn Bubley
Phase 1b Safety, Preliminary Anti-Leukemic Activity and Biomarker Analyses of the Polo-like Kinase 1 (PLK1) Inhibitor, Onvansertib, in Combination with Low-Dose Cytarabine or Decitabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Amer Zeidan, Alexander Spira, Pamela Becker, Prapti Patel, Gary Schiller, Michaela Tsai, Tara Lin, Eunice Wang, Maya Ridinger, Peter Croucher, Sandra Silberman, Mark Erlander, Jorge Cortes
A Phase 2 Study of Onvansertib (PCM-075) in Combination with Abiraterone and Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer
David J. Einstein, Atish Choudhury, Philip Saylor, Lillian Werner, Mark Erlander, Maya Ridinger, Glenn Bubley
Phase 1b Safety, Preliminary Anti-Leukemic Activity and Biomarker Analyses of the Polo-like Kinase 1 (PLK1) Inhibitor, Onvansertib, in Combination with Low-Dose Cytarabine or Decitabine in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Amer Zeidan, Alexander Spira, Pamela Becker, Prapti Patel, Gary Schiller, Michaela Tsai, Tara Lin, Maya Ridinger, Sandra Silberman, Mark Erlander, Jorge Cortes
Selective Polo-like Kinase 1 (PLK1) Inhibitor PCM-075 is Highly Active Alone and Shows Synergy When Combined with FLT3 Inhibitors in Models of Acute Myeloid Leukemia (AML)
Karena Kosco, Maya Ridinger, Penn Whitley, Antonella Ciavolella, Peter Croucher, Barbara Valsasina, Jeffrey N. Miner, Mark Erlander
Pharmacodynamic and Tumor Biomarker Analysis of a PLK1 Inhibitor, PCM-075, in a Phase 1b/2 Trial for Acute Myeloid Leukemia
Maya Ridinger, Karena Kosco, Latifa Hassaine, Shiloh Guerrero, Jeffrey N. Miner, Mark Erlander
Computationally Predicted Sensitivity of Clinical Cohorts Identifies Biomarkers Associated with Response to PCM-075, a PLK-1 Selective Inhibitor
Penn Whitley, Peter J P Croucher, Barbara Valsasina, Dario Ballinari, Italo Beria, Jeffrey N. Miner and Mark G. Erlander
Sensitivity of Triple Negative Breast Cancer Cell Lines to PCM-075, a Highly Selective Polo-like Kinase 1 Inhibitor
Jesse C. Patterson, Peter J P Croucher. Aleksandra Francovic, Dario Ballinari, Fabio Gasparri, Laura Giorgini, Penn Whitley, Barbara Valsasina, Marl Erlander and Michael B. Yafee
